Release Date: March 31, 2025
Expiration Date: March 31, 2026
Activity Overview
Recently approved anti-vascular endothelial growth factor (anti-VEGF) agents that target additional pathways and offer innovative delivery methods with longer-lasting effects provide advantages over older anti-VEGF agents in managing neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). In this program, expert faculty discuss the roles of ophthalmologists and optometrists in managing nAMD and DME in an evolving treatment landscape, from screening and diagnosis to referral and ongoing patient care.
This educational activity is an archive of the live symposium held on February 14, 2025.
Target Audience
This live educational activity is directed toward optometrists, ophthalmologists, and other eye care professionals.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the limitations of anti-VEGF intravitreal injection therapies in the treatment of nAMD and DME
- Summarize the latest clinical evidence supporting the use of novel therapies in the management of nAMD and DME
- Integrate current and emerging agents for nAMD and DME into clinical practice to reduce treatment burden
- Explain the role of eye care professionals in the optimal management of nAMD or DME
Adrienne W. Scott, MD, FASRS
Frederick M. Leader Professor of Ophthalmology
Associate Professor of Ophthalmology, Retina Division
Wilmer Eye Institute
Johns Hopkins University School of Medicine
Baltimore, MD
Disclosure: Grant/Research Support: Genentech/Roche; Consultant: Apellis, EyePoint, Genentech/Roche, Iveric Bio, Regeneron; Honorarium: Allergan/AbbVie, Regeneron; Material Support: Optos.
Justine Cheng, MD
Assistant Professor
Department of Ophthalmology and Vision Sciences
University of Illinois College of Medicine
Chicago, IL
Disclosure: Justine Cheng, MD, has no relevant financial relationships with ineligible companies.
Hong-Uyen Hua, MD
Assistant Professor of Clinical Ophthalmology
Bascom Palmer Eye Institute
University of Miami Health System
Miami, FL
Disclosure: Adviser: AbbVie, Alcon, Alimera Sciences/ANI Pharmaceuticals, Genentech.
Sherrol A. Reynolds OD, FAAO, FNAP
Professor of Optometry
Nova Southeastern University
College of Optometry
Fort Lauderdale, FL
Disclosure: Honorarium: American Diabetes Association, Genentech, Regeneron, Vision Service Plan (VSP).
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here